Bahija Jallal

Bio

Dr. Bahija Jallal has been appointed executive vice president, research & development with oversight for research and development activities based at MedImmune's Gaithersburg and Cambridge, UK sites. Dr. Jallal joined MedImmune as vice president, translational sciences, in March 2006 and in 2007 her responsibilities were expanded when she was appointed head, preclinical oncology. Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company's translational medicine group. Prior to Chiron, she worked at Sugen, Inc. where she held positions of increasing responsibility leading to senior director, research. Dr. Jallal received a master's degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.